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Introduction: Mesenchymal stem cells (MSCs) represent promising applications in rheumatoid arthritis (RA).
However, the inflammatory niche in the RA synovium could adversely affect MSC function. This study was designed
to investigate biologic and immunologic properties of synovium-derived MSCs (SMSCs) in RA, with particular focus
on whether cytokines can mediate increase of proliferation of T cells cocultured with SMSCs in RA.
Methods: Compared with SMSCs from eight healthy donors (HDs), SMSCs from 22 patients with RA (RAp) were
evaluated. The methyl thiazolyl tetrazolium (MTT) assay was used to assess cell-population doubling and viability.
Multipotentiality of SMSCs was examined by using appropriate culture conditions. Flow cytometry was used to
investigate the marker phenotype of SMSCs. Immunomodulation potential of SMSCs was examined by mixed
peripheral blood mononuclear cells (PBMCs) reactions, and then by PBMCs or synovial T cells with or without the
addition of inflammatory cytokines (interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), and interferon-γ
(IFN-γ)) after stimulation with phytohemagglutinin (PHA), respectively.
Results: SMSCs from RA patients (RA-SMSCs) showed normal population doubling, cell viability, multiple
differentiation characteristics, and surface markers. In either mixed PBMC reactions or PBMC proliferation stimulated
with PHA, RA-SMSCs showed normal immunomodulation function compared with SMSCs from healthy donors
(HD-SMSCs). However, the increase in proliferation of T cells was observed when IL-17A and TNF-α were added
alone or in combination.
Conclusions: Our data suggest that the inflammatory niche, especially these cytokines, may increase the
proliferation of T cells cocultured with SMSCs in RA.Introduction
Rheumatoid arthritis (RA) is a complex autoimmune
disorder involved with multiple systems. Its characteristic
is the destruction of cartilage and bone by the inflamma-
tory mediators, such as interleukin-17A (IL-17A), tumor
necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). The
etiology of RA is still under study, and multiple cells are
thought to contribute to the pathogenic progression, in
which T-cells [1] and fibroblast-like synoviocytes (FLSs)* Correspondence: lwp63@163.com; yangr@mail.sysu.edu.cn
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reproduction in any medium, provided the or[2] are involved in a complex network leading to joint
damage. Activation of Th1 cells and Th17 cells in the
development of cell-mediated autoimmune arthritis has
been investigated [3,4]. Conversely, Th2 cells and Treg
cells maintain homeostasis in RA and in animal models
of collagen-induced arthritis (CIA) [5,6].
Mesenchymal stem cells (MSCs) are multipotent pro-
genitor cells. Although MSCs originally were isolated from
bone marrow (BM), similar populations have been isolated
from other tissues, including the synovial membrane [7],
synovial fluid (SF) [8], tendon [9], periosteum [10], and
joint fat [11]. These cells have the ability to differentiate
into various other mesodermal cell lineages, including
chondrocytes, adipocytes, and osteoblasts [12]. AnotherLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical status of RAp and HD
RAp HD
Number of Patients 22 8
Sex
Men 11 (50%) 4 (50%)
Woman 11 (50%) 4 (50%)
Age (years) 42 (38 to 56) 40 (35 to 46)
Disease duration (years) 3.1 (0.2 to 5.5) 2.6 (0.1 to 4.6)
Treatment, patients (%)
None 15 (68%) 7 (87.5%)
MTX 2 (9%) -
MTX + SSZ 2 (9%) -
NSAIDs - 1 (12.5%)
Otherb 3 (14%) -
VAS 14 (5 to 35) 1 (0 to 2)
bOther treatments may have included corticosteroids, azathioprine, or
leflunomide. In the HD group, disease duration refers to the duration of
meniscus injury.
HD, healthy donor; MTX, methotrexate; Rap, patients with rheumatoid arthritis
(RA); SSZ, sulfasalazine; NSAIDs, nonsteroidal antiinflammatory drugs; VAS,
visual analogue score.
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of multiple lymphocytes [13,14]. Because of their immuno-
suppression effects, MSCs represent promising applications
in treatment of acute graft-versus-host disease [15].
However, the specific mechanisms by which bone marrow-
derived MSCs (BMSCs) exhibit their immnoregulatory
ability remain under discussion, and a difference is noted
between the therapeutic effects for CIA models by MSCs
[16,17]. The feasibility and safety of MSCs treatment have
yet to be determined in larger cohort studies [18,19].
Recent studies have focused on an important role of
synovium-derived mesenchymal stem cells (SMSCs) in
local environment remediation [20,21]. It has been dem-
onstrated that these processes contain direct recruitment
of synovial cells into chondral defects [22] and their
homing to injured sites [20]. With respect to RA, it is
still important to consider the degree of the disease
related to the inflammatory milieu, because inflammatory
cytokines, such as such as IL-17A, TNF–α, and IFN-γ, have
previously been shown to influence the functions of FLS
and MSCs in the inflamed synovium [23]. Before contem-
plating clinical studies with MSCs in patients with RA
(RAp), the proliferative and immunomodulatory capacity of
SMSCs in this inflammatory condition must be explored.
Inspired by the study of Farida Djouad and collegues [24],
which revealed a reversal of immunosuppressive properties
of MSCs by environmental parameters related to inflamma-
tion in CIA, we hypothesized that the immunomodulation
function of SMSCs by IL-17A or TNF-α in RA should be
reduced. Therefore, this study was designed to investigate
biologic and immunologic properties of SMSCs in RA,
especially focusing on whether cytokines can mediate
the increase of proliferation of T cells cocultured with
SMSCs in RA.
Methods
SMSCs from healthy donors (HD-SMSCs) and patients
with RA (RA-SMSCs)
The study was approved by the Ethics Committee at Sun
Yat-sen Memorial Hospital, and informed consent was
obtained from all study subjects. Synovial tissue biopsies
from the suprapatella pouch were obtained from 22 RAp
and eight HD (For practical reasons, we chose patients
with meniscus injury who were undergoing arthroscopy,
and without any systemic immune disease or connective
tissue disease, as the healthy donors) by using 3.5-mm
grasping biopsy forceps under direct vision with arthros-
copy. The RAp fulfilled the American College of Rheuma-
tology criteria for RA [25]. The degree of macroscopic joint
inflammation was evaluated by using the Visual Analogue
Score (VAS). Scores (scaled between 0 and 100) were based
on visual image of vasculature (redness and vessels due to
hyperemia) in arthroscopy [26]. Synovial tissues were finely
minced and digested with 0.4% collagenase (Gibco BRL Co.Ltd.,Gaithersburg, MD, USA) in high-glucose Dulbecco
modified Eagle medium (DMEM) containing 10% fetal bo-
vine serum (FBS), 100 U/ml penicillin, and 100 U/ml
streptomycin. After overnight incubation at 37°C, cells
were collected by centrifugation, washed twice, resus-
pended in high-glucose DMEM supplemented with 10%
FBS, plated in a T25 culture flask, and allowed to attach
for 7 days. Nonadherent cells were removed by changing
the medium. Cells were passaged when reaching near con-
fluence according to previous report [7].
Peripheral blood mononuclear cells (PBMCs) isolation
and synovial T-cells expansion
PBMCs were from HD and RAp by Ficoll-Hypaque
density gradient (density, 1.077 g/L; Sigma). The clinical
status of two groups is described in Table 1.
Synovial T cells were expanded from synovial tissues of
RAp cultured for 14 days in RPMI-1640 medium supple-
mented with 10% FBS, in the presence of recombinant IL-2
(20 IU/ml; R&D Systems, Minneapolis, MN, USA). Cultures
were fed every 3 days. T cells were then collected and ana-
lyzed with a cell sorter (FACS Vantage SE cell sorter; Becton
Dickinson). More than 95% of the cells expressed CD3.
SMSCs population doubling and viability test
SMSCs (P4) were vaccinated into 96-well plates at a
concentration of 1 × 104/ml, in a final volume of 100 μl
fresh medium (10% FBS + high-glucose DMEM). For
cell counting, three wells of each sample were digested by
using 0.25% trypsin-ethylenediamine tetraacetic acid per
day up to 12 days. With these data for cell-population
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methyl thiazolyl tetrazolium (MTT, 5 mg/ml; Sigma),
dimethylsulfoxide (DMSO; Sigma), and an EL800 micro-
plate reader (BioTek Instruments, Winooski, VT, USA)
that was to detect absorbance at 490 nm, we made the
SMSCs viability curves in the same way, according to
the day and the absorbance. Fresh medium was used as
a negative control.In vitro differentiation potential assay
For the in vitro differentiation assays, three procedures
(adipogenic differentiation, osteogenic differentiation, and
chondrogenic differentiation) were used, as previous
described [7]. The intracellular lipid accumulation as an
indicator was visualized on day 21 with Oil Red O staining.
The alkaline phosphatase (ALP) of SMSCs was assayed by
using Cell ALP Staining assay (Nanjing Jiancheng, China),
according to the recommendations of the manufacturers
on day7 and alizarin red staining (AR-S, 1%, pH 7.2; Sigma)
on day 28, respectively. The chondrogenic differentiations
were confirmed with alcian blue staining. Meanwhile,
the experimental controls were established by culture
of SMSCs (P4) in fresh medium, and only fresh medium
was used as a negative control. All measurements were
tested in triplicate. An inverted phase-contrast microscope
(Nikon Eclipse Ti-S; Nikon Corporation, Japan) visualized
the images.
For quantitative assay, three procedures (adipogenic
differentiation value, calcium deposits, alcian blue inten-
sity) were used as previous represented [27,28].Immuno-phenotype of SMSCs
After treatment with 0.25% trypsin-ethylenediamine tetra-
acetic acid, SMSCs (P4) were then resuspended in PBS
containing 0.5% BSA and 0.1% sodium azide. Cell aliquots
(1 × 106 cells/ml) were incubated on ice with conjugated
mAbs against CD105, CD166, CD44, CD90, CD14, CD34,
CD45, and HLA-DR (Table 2) or conjugated isotypic
controls. Flow cytometry was performed on a FACScan
laser flow-cytometry system (Becton Dickinson, San Jose,Table 2 Antibodies used to detect phenotype synovium-deriv









All antibodies were mouse IgG isotype antibodies obtained from commercial sourceCA, USA), and data were analyzed with the CellQuest
software (BD Bioscience, San Jose, CA, USA).Immunomodulation potential of SMSCs
The suppressive effects of SMSCs (P4) on mixed PBMCs
reaction (MLR) and PBMCs proliferation stimulated by
phytohemagglutinin (PHA) (4 μg/ml; Roche, Mannheim,
Germany) were measured by using the MTT assay [29]
and the 3H-TdR assay [30], as described previously. SMSCs
were seeded in 96-well culture plates for 6 hours for
adherence, and then irradiated (30 Gy) with Co60.
For the MLR, allogeneic PBMCs (15 × 104 cells/cm2)
from an HD were mixed with PBMCs from another un-
related HD in identical mounts. The mixed PBMCs were
then mixed with different ratios (3 × 105 cells/cm2 = 1:1
SMSC: PBMCs ratio, 15 × 104 cells/cm2 =1:2, 6 × 104
cells/cm2 =1:5, 3 × 104 cells/cm2 = 1:10, 15 × 103 cells/
cm2 = 1:20) of SMSCs (experiment wells) or without
SMSCs (blank wells) in 96-well culture plates to ensure
efficient cell-cell contact for 5 days in 0.2 ml modified
RPMI-1640 medium (Gibco) supplemented with 10%
FBS.
The PBMCs proliferation assay only uses one autologous
or allogeneic PBMCs reaction (30 × 104 cells/cm2) from a
healthy donor or patient with RA stimulated with PHA.
Inhibitory or proliferative effects were measured on day 5
by using the MTTassay or the 3H-TdR assay. All measure-
ments were performed in triplicate. Results were expressed
as the mean (% inhibition or % proliferation) ± SD.Data analysis
Continuous variables were expressed as the mean ± SD,
and categoric variables were presented as frequencies and
percentages. The significance of the results was determined
by using the unpaired Student t test, χ2 test, and repeated-
measure tests with Bonferroni correction. Data analysis was
performed with statistical software (SPSS, version 15.0 for
Windows; SPSS Inc., Armonk, NY, USA). P < 0.05 was
considered statistically significant.ed mesenchymal stem cells (SMSCs) with flow cytometry
/ml) Source
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)
Southern Biotech (Birmingham, AL, USA)
Becton Dickinson (Bedford, MA, USA)
Caltag (Burlingame, CA, USA)
Becton Dickinson (Bedford, MA, USA)
Becton Dickinson (Bedford, MA, USA)
AbD Serotec (MorphoSys, UK)
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)
s.
Figure 1 (See legend on next page.)
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Figure 1 Synovium-derived mesenchymal stem cells (SMSCs) triple differentiation potentials from healthy donors and patients with
rheumatoid arthritis (RA). (A, B) Morphologic characteristics of SMSCs for adipogenic, osteogenic, and chondrogenic differentiation evaluated
with the inverted phase-contrast microscope; SMSCs from RA patients (RA-SMSCs) have the same morphologic properties as SMSCs from healthy
donors (HD-SMSCs). Adipocytes were filled with many fat vacuoles, and Red Oil O was used to stain the fat vacuoles of adipocytes (A1, B1:
×100). Osteocytes were stained for alkaline phosphatase (ALP) with the Cell ALP assay (A2, B2: ×100) and for calcium deposition by using alizarin
red-S (A3, B3: ×100). Chondroblast differentiation from SMSCs was displayed as cartilage-specific metachromasia with alcian blue (A4, B4: ×100).
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Population doubling and viability of SMSCs from RAp
are normal
The RA-SMSCs growth curves (data not shown) have
the same tendency as those for HD-SMSCs. The SMSCs
population-doubling data of these two groups at each
day (1 to 12 days) were tested by repeated-measures
tests with Bonferroni correction, and the statistical result
indicates that no statistically significant difference was
present in SMSCs population doubling between RAp
and HD (P = 0.157). For SMSCs viability at each point of
time from 1 to 12 days, the difference of optical density
(OD) at 490 nm between RAp and HD also was not statis-
tically significant, as determined by cellular viability assays
(P = 0.161).
Triple differentiation potentials of RA-SMSCs in vitro were
not changed
In both groups, obvious differentiated adipocytes and
osteocytes were detected as early as the day 14 after being
induced for adipogenic and osteogenic differentiation, and
obvious differentiated chondrocytes were seen at about 21
days since induction. For adipogenesis, the cells displayed
the accumulation of lipid vacuoles, which stained with
oil red O (Figure 1A1; B1). We analyzed the adipogenic
differentiation value results by using IPP 6.0; no significant
difference was found between RA-SMSCs and HD-SMSCs
(P = 0.193). For osteogenesis, SMSCs from both popula-
tions treated with osteogenic medium underwent a change
in their morphology from spindle shaped to cuboidal, and
formed large nodules that stained for ALP and alizarin red
(Figure 1A2, 3; B2, 3). For quantitative assay of mineral
deposits, absorption of the dye at 562 nm revealed no
significant difference in alizarin red-positive mineralized
matrices (P = 0.088). For chondrogenesis, the cells dis-
played cartilage-specific metachromasia with alcian
blue in vitro (Figure 1A4; B4). The alcian blue staining
intensity of pellets in both groups had no significant
difference (P = 0.075).
Phenotypic characterization
By FACS analysis, for SMSCs from both tissues, the
expression of CD14, CD34, CD45, and HLA-DR was
negative, and the expression of CD44, CD90, CD105, and
CD166 was positive (Figure 2). The expression intensity of
each marker was not statistically different between thetwo populations (P > 0.05). Indeed, the cell populations
isolated from two different tissues displayed a similar
phenotype, just as the typical MSCs did [12].Normal suppressive potential of RA-SMSCs on either MLR
or PBMCs proliferation stimulated with PHA
As shown in Figure 3, no statistically significant reduc-
tion in suppressive potential (percentage inhibition) of
RA-SMSCs was found on MLR at all five ratios, compared
with the percentage inhibition of HD-SMSCs (Figure 3A2,
A3; P > 0.05). Similarly, RA-SMSCs produced no statisti-
cally significant decreased inhibitory effect on autologous
or allogeneic PBMCs proliferation (Figure 3B2, B3; P >
0.05), ranging from a SMSC-to-PBMC ratio of 1:20 to 1:1.
Furthermore, in either of them, the 3H-TdR assay data
also suggested a significant relation between dose and in-
hibition of SMSCs from both populations was established.Involvement of IL-17A, TNF-α in the increase of the prolif-
eration of T cells cocultured with SMSCs
To understand why SMSCs do not display any immuno-
suppressive effects in RAp, we tested the potential role
of the inflammatory environment on SMSCs behavior.
We therefore investigated the role of various cytokines
(IL-17A, TNF-α, IFN-γ) on the interaction of synovial T
cells from RAp with autologous SMSCs. Because the
best ratio of SMSCs to PBMCs was 1:1, we used this cell
ratio for subsequent experiments. Irradiated SMSCs and
synovial T cells were cultured alone or were cocultured
at a 1:1 ratio for 24 hours in the presence or absence of
PHA (4 μg/ml), and exogenous IL-17A (50 ng/ml), TNF-α
(50 ng/ml), or IFN-γ (50 ng/ml) was added either alone
or in combination. Each experiment was performed in
triplicate and repeated at least 3 times. The coculture of
HD-SMSCs and synovial T cells from RAp were used as
the experimental control.
As shown in Figure 4A1, RA-SMSCs totally inhibited
the autologous response of synovial T-cells (P < 0.05). In
contrast, the proliferation of synovial T cells was increased
when cultured with RA-SMSCs in the presence of IL-17A
or TNF-α (P < 0.05; Figure 4A2). IL-17A and TNF-α had
no effect on RA-SMSC or synovial T cells cultured alone
(P > 0.05; Figure 4A3). No effect was observed when
IFN-γ was added to the reactions (P > 0.05). Moreover,
HD-SMSCs were unable to suppress the proliferative
Figure 2 (See legend on next page.)
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Figure 2 Phenotyping of synovium-derived mesenchymal stem cells (SMSCs) for typical mesenchymal stromal cell-surface markers.
SMSCs from healthy donors (HD-SMSCs) and SMSCs from patients with rheumatoid arthritis (RA-SMSCs) were negative for the expression of CD14,
CD34, CD45, and HLA-DR, and were positive for CD44, CD90, CD105, and CD166. Red lines indicate background fluorescence obtained with
isotype control IgG. x axis, fluorescence intensity; y axis, cell counts.
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alone or in combination (Figure 4B; P < 0.05).
Discussion
We demonstrated that RA-SMSCs showed normal popu-
lation doubling, cell viability, multiple differentiation char-
acteristics, and surface markers; and also in either MLR
or PBMCs proliferation stimulated with PHA, RA-SMSCs
showed normal immunomodulation function compared
with HD-SMSCs. Impressively, the increase of proliferation
of T cells cocultured with SMSCs was observed when
IL-17A and TNF-α were added alone or in combination.
Although recent studies suggested that the imbalance
of Th17/Treg cells plays a crucial role in the progression
of RA [31], the mechanisms leading to their study in the
RA synovium remain unknown. Moreover, even through
some cytokines, especially IL-6, IL-23, and transforming
growth factor β (TGF-β), which facilitate the differenti-
ation of Th17 [32], are demonstrated in the RA synovium;Figure 3 Normal immunosuppressive potential of synovium-derived m
(RA-SMSCs). (A1) The differences of absorbance between 0 days and 5 da
mononuclear cells (PBMCs) from a healthy donor (P > 0.05) and the PBMCs
PBMCs, however, the absorbance at 5 days was significantly higher than the v
mesenchymal stem cells of healthy donors (HD-SMSCs), no statistically signific
reaction (MLR) was found at all five ratios (P > 0.05). (B1) In autologous or allo
0 days and 5 days without PHA were not significant (P > 0.05), whereas the v
(P < 0.05). (B2, B3) Percentage inhibition of RA-SMSCs on PBMCs proliferation
(P < 0.05). Results were recorded as mean absorbance (optical density (OD)) ±
respectively. The percentage inhibition values were calculated by using the fo
%inhibition = 1 − (CPM(exp) − CPM(adj))/CPM(bla). OD(exp), OD(adj) and OD(
(only SMSCs), and blank wells, respectively, and CPM(exp), CPM(adj), and CPM
Results were finally expressed as the mean (% inhibition) ± SD.the other cytokines, such as IFN-γ, which counteract their
differentiation, are also found [1,2]. In addition, the
immune regulation of T cells by MSCs has also been
demonstrated [7,33]. Although previous studies have
assumed that the functional deficiency of reg cells in RA
may be the reason [34], others have proposed that the
interaction of BMSCs with T cells promotes the activation
and expansion of Th17 cells [35]. In conclusion, among
the cytokines produced by FLSs and synovial T cells, IL-
17A, TNF–α, and IFN-γ have been found to play pivotal
roles in RA [3,4,36]. We thus investigated whether these
cytokines could influence the immunosuppressive proper-
ties of SMSCs.
To date, only a few studies have explored MSCs in
RA, and these were focused on BMSCs [35,37]. To our
knowledge, our study is the first investigation describing
the interaction between the inflammatory niche and
RA-SMSCs. In RA, in vivo MSCs showed an inflamma-
tion-related reduction in numbers. Extensive proliferationesenchymal stem cells of patients with rheumatoid arthritis
ys were not statistically significant for the allogeneic peripheral blood
from another unrelated healthy donor (P > 0.05); for the mixed
alue at 0 days (P < 0.05). (A2), (A3) Compared with synovium-derived
ant reduction in suppressive potential (% inhibition) on mixed PBMCs
geneic PBMCs proliferation assay, the differences of absorbance between
alue for 5 days with PHA was significantly higher than the value at 0 days
induced by PHA was similar with the values of HD-SMSCs at varied ratios
standard deviation (SD) and as mean counts per minute (CPM) ± SD,
llowing formulae: %inhibition = 1 − (OD(exp) − OD(adj))/OD(bla) or
bla) represent the mean absorbance of experimental wells, adjusted wells
(bla) represent the mean counts per minute of the corresponding wells.
Figure 4 Involvement of IL-17A, TNF-α in the increase of the proliferation of T cells co-cultured with SMSCs. (A1, B1) In synovial T cells
proliferation assay, the differences of absorbance between 0 days and 5 days without PHA were not significant (P > 0.05), whereas the value for 5
days with PHA was significantly higher than the value at 0 days (P < 0.05); in SMSCs proliferation assay, no differences were noted between 0
days and 5 days with or without PHA; in the coculture of synovial T cells and SMSCs, the absorbance for 5 days with PHA was significantly lower
than the value at 0 days or 5 days without PHA (P < 0.05). (A2, B2) In synovial T cells activated by PHA and SMSCs cocultured in the presence of
cytokines assay, the increase of the proliferation (% proliferation) of T cells was significant in the presence of IL-17A or TNF-α (P < 0.05). However,
no effect was observed when IFN-γ was added (P > 0.05). In addition, the increase of proliferation was significant when cytokines were added in
combination (P < 0.05). (A3, B3) IL-17A and TNF-α had no effect on RA-SMSC or synovial T-cells cultured alone at 5 days with or without PHA
(P > 0.05). Results were recorded as mean absorbance (optical density (OD)) ± standard deviation (SD) and as mean counts per minute (CPM) ± SD,
respectively. The percentage proliferation values were calculated by using the following formulae: % proliferation = (OD(exp) − OD(adj))/OD(bla) or %
proliferation = (CPM(exp) − CPM(adj))/CPM(bla). OD(exp), OD(adj), and OD(bla) represent the mean absorbance of experimental wells, adjusted wells
(only SMSCs), and blank wells, respectively, and CPM(exp), CPM(adj), and CPM(bla) represent the mean counts per minute of the corresponding wells.
Results were finally expressed as the mean (% proliferation) ± SD.
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[38]. Clonal BMSCs from RAp (RA-BMSCs) were more
heterogeneous in their proliferative capacity and, on aver-
age, grew more slowly than clonal BMSCs from patients
with osteoarthritis. This could be explained by variable
premature telomere shortening previously observed for
RA-BMSCs [37]. Our data suggest that RA-SMSCs showed
normal biologic characteristic, such as cell-population
doubling, cell viability, multiple differentiation, and surface
markers, compared with HD-SMSCs. Previous study has
suggested a negative relation between SMSC chondrogenic
and clonogenic capacities and VAS in RA [39], and our
study found a negative relation between alcian blue
intensity and VAS (data not show) could explain normal
biological property. As VAS of RAp in our study was low
(Table 1), chondrogenic capacities may be affected by this
degree of clinical status. Moreover, previous SMSCs were
isolated from synovial tissues at the time of arthroplasty
for degenerative OA or RA [40], and the VAS of these
patients was almost as high.
Although RA-BMSCs seem to be similar to normal
BMSCs, in that they can also inhibit the proliferation ofautologous and allogeneic PBMCs in vitro [41], Evangelia
Yannaki [42] demonstrated that BMSCs lose their immuno-
modulatory properties when infused in the inflammatory
micromilieu of RA. They found conditioning of the recipi-
ent with bortezomib alters the disease microenvironment,
enabling BMSCs to modulate arthritis. The discrepancy of
MSCs function between in vitro and in vivo conditions,
implies that a common endogenous stimulus may alter
the in vivo performance of MSCs and that the immune
privilege ascribed to MSCs may be susceptible to the
influence of the microenvironment. We showed that the
increase of proliferation of T cells cocultured with SMSCs
was observed when IL-17A and TNF-α were added alone
or in combination in vitro. Thus, we speculated that those
cytokines may influence the immunosuppressive properties
of SMSCs in RA. In vitro, failure of SMSCs to induce
immunomodulation in severely inflammatory conditions
may reflect the dynamic nature and complex network of
specific microenvironments in vivo.
The major limitation of the present study is that we
did not investigate the mechanism by which IL-17A and
TNF-α affect proliferation of T cells. Although previous
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ties of MSCs [24], but a direct effect on T cells, rendering
them resistant to suppression, cannot be excluded. Further
research is required.
Conclusion
Our findings demonstrate the existence of SMSCs in RA
and the inflammatory micromilieu of RA increases the
proliferation of T cells cocultured with SMSCs. This
information furthers our understanding of the etiology
of RA, and strategies to alter the inflammatory milieu
before SMSC action may be of critical importance.
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